TW200526777A - Combinations for the treatment of proliferative diseases - Google Patents

Combinations for the treatment of proliferative diseases Download PDF

Info

Publication number
TW200526777A
TW200526777A TW093133826A TW93133826A TW200526777A TW 200526777 A TW200526777 A TW 200526777A TW 093133826 A TW093133826 A TW 093133826A TW 93133826 A TW93133826 A TW 93133826A TW 200526777 A TW200526777 A TW 200526777A
Authority
TW
Taiwan
Prior art keywords
cell
compound
reduces
biological activity
preparation
Prior art date
Application number
TW093133826A
Other languages
English (en)
Chinese (zh)
Inventor
M James Nichols
Margaret S Lee
Curtis Keith
Yanzhen Zhang
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of TW200526777A publication Critical patent/TW200526777A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW093133826A 2003-11-12 2004-11-05 Combinations for the treatment of proliferative diseases TW200526777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
TW200526777A true TW200526777A (en) 2005-08-16

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093133826A TW200526777A (en) 2003-11-12 2004-11-05 Combinations for the treatment of proliferative diseases

Country Status (13)

Country Link
EP (1) EP1689352A2 (ja)
JP (1) JP2007524657A (ja)
KR (1) KR20060118514A (ja)
AR (1) AR046841A1 (ja)
AU (1) AU2004289311A1 (ja)
BR (1) BRPI0416390A (ja)
CA (1) CA2545423A1 (ja)
IL (1) IL175611A0 (ja)
IS (1) IS8496A (ja)
NO (1) NO20062358L (ja)
RU (1) RU2006120491A (ja)
TW (1) TW200526777A (ja)
WO (1) WO2005046607A2 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070865A1 (es) * 2008-03-18 2010-05-12 Genentech Inc Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2005046607A3 (en) 2012-12-20
IS8496A (is) 2006-06-02
JP2007524657A (ja) 2007-08-30
RU2006120491A (ru) 2007-12-20
KR20060118514A (ko) 2006-11-23
IL175611A0 (en) 2008-04-13
EP1689352A2 (en) 2006-08-16
NO20062358L (no) 2006-07-12
CA2545423A1 (en) 2005-05-26
AU2004289311A1 (en) 2005-05-26
AR046841A1 (es) 2005-12-28
WO2005046607A2 (en) 2005-05-26
BRPI0416390A (pt) 2007-02-21

Similar Documents

Publication Publication Date Title
US11865094B2 (en) Treatment and diagnosis of melanoma
US20050137185A1 (en) Combinations of drugs for the treatment of neoplasms
CN101217956A (zh) 用于治疗肿瘤的组合物和方法
US20050054708A1 (en) Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) Combinations for the treatment of proliferative diseases
US20130203618A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferative disorders
WO2004007676A2 (en) Combination therapy for the treatment of neoplasms
TW200526777A (en) Combinations for the treatment of proliferative diseases
WO2014015118A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferative disorders
MXPA06005456A (en) Combinations for the treatment of proliferative diseases
TW202122088A (zh) 波齊替尼(poziotinib)與vegfr2抑制劑的組合及其使用方法
WO2023015149A1 (en) Treatment of non-small cell lung cancer with poziotinib
WO2004073631A2 (en) Combination therapy for the treatment of neoplasms